Kurt Knab - Evolus Vice President of Sales
| EOLS Stock | USD 13.41 0.16 1.18% |
President
Mr. Kurt Knab is Vice President of Sales of the Company. Mr. Knab joins Evolus from Medline Industries where he served as Vice President of Business Development and Sales. Prior to that, Kurt spent sixteen years at LifeCell Corporation where he held various roles in sales leadership and ultimately served as Vice President, U.S. Sales for 4 years. At LifeCell he was responsible for leading the commercial efforts of the LifeCell entire portfolio including Alloderm, Strattice, and Revolve since 2018.
| Tenure | 7 years |
| Address | 520 Newport Center Drive, Newport Beach, CA, United States, 92660 |
| Phone | 949 284 4555 |
| Web | https://www.evolus.com |
Evolus Management Efficiency
The company has return on total asset (ROA) of (0.0993) % which means that it has lost $0.0993 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.6168) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 2.82 in 2025, whereas Return On Tangible Assets are likely to drop (0.48) in 2025. At this time, Evolus' Intangible Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.57 in 2025, whereas Net Tangible Assets are likely to drop (62 M) in 2025.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Lisa Escudero | Phibro Animal Health | 63 | |
| Juan Sanchez | Intracellular Th | 53 | |
| Mark Neumann | Intracellular Th | 62 | |
| Daniel Bendheim | Phibro Animal Health | 52 | |
| Ramon Fuenmayor | Phibro Animal Health | N/A | |
| David Gaffin | Alkermes Plc | 52 | |
| Shirley Kuhlmann | Collegium Pharmaceutical | 40 | |
| William PPool | Prestige Brand Holdings | 59 | |
| Thomas Dagger | Phibro Animal Health | 66 | |
| Luis Aragon | Procaps Group SA | 61 | |
| Scott Dreyer | Collegium Pharmaceutical | 53 | |
| Michael Landine | Alkermes Plc | 70 | |
| Joseph Ciaffoni | Collegium Pharmaceutical | 53 | |
| Michael Olchaskey | Intracellular Th | N/A | |
| Samson Li | Phibro Animal Health | 53 | |
| Michael Giambalvo | Phibro Animal Health | N/A | |
| Jonathan Bendheim | Phibro Animal Health | 49 | |
| John Condon | Intracellular Th | N/A | |
| Robert Davis | Intracellular Th | 74 | |
| Mauricio Caballero | Procaps Group SA | 48 | |
| Jack MBA | Supernus Pharmaceuticals | 64 | |
Management Performance
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0993 |
Evolus Inc Leadership Team
Elected by the shareholders, the Evolus' board of directors comprises two types of representatives: Evolus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evolus. The board's role is to monitor Evolus' management team and ensure that shareholders' interests are well served. Evolus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evolus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Crystal Muilenburg, Vice President Corporate Communications and Public Relations | ||
| Jessica Novak, Senior Resources | ||
| Tomoko YamagishiDressler, Chief Officer | ||
| CCFP DipSportMed, Chief RD | ||
| David Erickson, VP Relations | ||
| David Moatazedi, President CEO, Director | ||
| Kurt Knab, Vice President of Sales | ||
| Sandra Beaver, Chief Officer | ||
| Jeffrey Plumer, General Counsel | ||
| Nareg Sagherian, Head Communications |
Evolus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evolus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.62 | ||||
| Return On Asset | -0.0993 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.21) % | ||||
| Current Valuation | 904.11 M | ||||
| Shares Outstanding | 63.32 M | ||||
| Shares Owned By Insiders | 12.30 % | ||||
| Shares Owned By Institutions | 79.27 % | ||||
| Number Of Shares Shorted | 5.93 M | ||||
| Price To Earning | (5.55) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.